MX367908B - Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina. - Google Patents

Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina.

Info

Publication number
MX367908B
MX367908B MX2017001930A MX2017001930A MX367908B MX 367908 B MX367908 B MX 367908B MX 2017001930 A MX2017001930 A MX 2017001930A MX 2017001930 A MX2017001930 A MX 2017001930A MX 367908 B MX367908 B MX 367908B
Authority
MX
Mexico
Prior art keywords
preparing
synthetic intermediates
tetrahydroquinoline derivatives
derivatives
preparation
Prior art date
Application number
MX2017001930A
Other languages
English (en)
Spanish (es)
Other versions
MX2017001930A (es
Inventor
Ford John
Paulus Gerardus Seerden Johannes
Ledru Amandine
Original Assignee
Dezima Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51429345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367908(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dezima Pharma B V filed Critical Dezima Pharma B V
Publication of MX2017001930A publication Critical patent/MX2017001930A/es
Publication of MX367908B publication Critical patent/MX367908B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MX2017001930A 2014-08-12 2015-07-29 Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina. MX367908B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (fr) 2014-08-12 2015-07-29 Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine

Publications (2)

Publication Number Publication Date
MX2017001930A MX2017001930A (es) 2018-03-01
MX367908B true MX367908B (es) 2019-09-11

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001930A MX367908B (es) 2014-08-12 2015-07-29 Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina.

Country Status (26)

Country Link
US (1) US10112904B2 (fr)
EP (2) EP3180314B1 (fr)
JP (1) JP6670310B2 (fr)
KR (1) KR102572626B1 (fr)
CN (1) CN107108558B (fr)
AR (1) AR101509A1 (fr)
AU (1) AU2015302407B2 (fr)
BR (1) BR112017002873B1 (fr)
CA (1) CA2958040C (fr)
CL (1) CL2017000367A1 (fr)
DK (1) DK3180314T3 (fr)
EA (1) EA034357B1 (fr)
ES (1) ES2926775T3 (fr)
HR (1) HRP20221061T1 (fr)
HU (1) HUE059947T2 (fr)
IL (1) IL250525B (fr)
LT (1) LT3180314T (fr)
MA (1) MA40378B1 (fr)
MX (1) MX367908B (fr)
PL (1) PL3180314T3 (fr)
PT (1) PT3180314T (fr)
RS (1) RS63575B1 (fr)
SG (1) SG11201701077XA (fr)
SI (1) SI3180314T1 (fr)
TW (1) TWI691490B (fr)
WO (1) WO2016024858A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022185120A1 (fr) 2021-03-05 2022-09-09 Newamsterdam Pharma B.V. Obicetrapib pour le traitement de démences
KR20240040767A (ko) 2021-07-26 2024-03-28 뉴암스테르담 파마 비.브이. His 저감반응자의 치료
WO2023129595A1 (fr) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Combinaison d'obicetrapib et d'inhibiteur de sglt2
TW202409008A (zh) 2022-07-05 2024-03-01 荷蘭商新阿姆斯特丹製藥公司 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體
WO2024042061A1 (fr) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Polythérapie d'obicetrapib et d'ézétimibe et compositions pharmaceutiques à dose fixe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2002253448B2 (en) * 2001-04-30 2007-07-05 Pfizer Products Inc. Compounds useful as intermediates for 4-aminoquinoline derivatives
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200808731A (en) * 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法

Also Published As

Publication number Publication date
PT3180314T (pt) 2022-09-02
KR102572626B1 (ko) 2023-08-30
EP3180314A1 (fr) 2017-06-21
SG11201701077XA (en) 2017-03-30
JP6670310B2 (ja) 2020-03-18
EA201790364A1 (ru) 2017-07-31
CA2958040A1 (fr) 2016-02-18
AU2015302407B2 (en) 2019-09-19
MA40378B1 (fr) 2022-10-31
US20170267640A1 (en) 2017-09-21
ES2926775T3 (es) 2022-10-28
CN107108558A (zh) 2017-08-29
AR101509A1 (es) 2016-12-21
BR112017002873A2 (pt) 2018-07-17
EP3180314B1 (fr) 2022-06-22
MA40378A (fr) 2017-06-21
HRP20221061T1 (hr) 2022-11-25
JP2017524742A (ja) 2017-08-31
EP4083022A1 (fr) 2022-11-02
RS63575B1 (sr) 2022-10-31
PL3180314T3 (pl) 2022-11-21
HUE059947T2 (hu) 2023-01-28
AU2015302407A1 (en) 2017-03-02
SI3180314T1 (sl) 2022-11-30
CL2017000367A1 (es) 2018-02-09
LT3180314T (lt) 2022-11-10
TW201613868A (en) 2016-04-16
IL250525B (en) 2019-08-29
EA034357B1 (ru) 2020-01-30
BR112017002873B1 (pt) 2023-03-28
KR20170102204A (ko) 2017-09-08
CN107108558B (zh) 2019-11-19
CA2958040C (fr) 2022-09-13
BR112017002873A8 (pt) 2022-11-08
WO2016024858A1 (fr) 2016-02-18
TWI691490B (zh) 2020-04-21
DK3180314T3 (da) 2022-08-29
US10112904B2 (en) 2018-10-30
IL250525A0 (en) 2017-03-30
MX2017001930A (es) 2018-03-01

Similar Documents

Publication Publication Date Title
AU2019268063A1 (en) Compositions for modulating sod-1 expression
EP3389725A4 (fr) Compositions et méthodes pour le traitement de maladies du système nerveux central
EP3177732A4 (fr) Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
EP3261440A4 (fr) Méthodes et compositions de traitement de maladies oculaires génétiques
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
EP3119913A4 (fr) Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique
EP3377090A4 (fr) Méthodes de traitement de troubles associés aux acides biliaires
EP3503906A4 (fr) Méthodes de traitement de troubles associés aux acides biliaires
EP3096617A4 (fr) Compositions et méthodes de traitement de maladies oculaires
EP3157531A4 (fr) Procédés et compositions pour la stimulation du système entéro-endocrinien intestinal pour le traitement de maladies ou d'états pathologiques associées à celui-ci
MX2017001930A (es) Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina.
EP3182989A4 (fr) Méthodes et compositions destinées à prévenir et à traiter une maladie
EP3182979A4 (fr) Nouvelles compositions et méthodes utiles pour traiter ou prévenir des maladies ou des troubles hépatiques et favoriser la perte de poids
EP3110446A4 (fr) Procédés et compositions pour le traitement de maladies associées à siglec-8
EP3131556A4 (fr) Méthodes et compositions pour le traitement de maladies liées à la bpco
EP3263119A4 (fr) Composition comprenant des vésicules extracellulaires dérivées de bactéries de bacillus sp. pour le traitement de maladies associées à la grossesse
EP3348273B8 (fr) Compositions à base de protéines et de xyloglucane pour le traitement de troubles intestinaux
EP3192875A4 (fr) Composition pharmaceutique à libération prolongée destinée au traitement et à la prévention de maladies ophtalmiques
EP3169405A4 (fr) Méthodes, composés et compositions pour le traitement de maladies musculo-squelettiques
EP3164132A4 (fr) Méthodes et compositions pour le traitement de maladies et d'affections
EP3326638A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur derosa rugosa
EP3501524A4 (fr) Utilisation de la phytosphingosine-1-phosphate ou d'un dérivé de celle-ci en tant qu'activateur immunitaire ou composition pharmaceutique pour le traitement de la démence
EP3156054A4 (fr) Médicament pour la prévention et/ou le traitement de maladies induites par le stress
EP3107534A4 (fr) Compositions et procédés pour le traitement de maladies neurodégénératives

Legal Events

Date Code Title Description
FG Grant or registration